Sold as Stadol Preservative Free, Stadol. Every FDA application for this active ingredient: 2 branded and 14 generic.
As of Nov 15, 2026, FDA lists 16 applications for Butorphanol Tartrate (sold as Stadol Preservative Free, Stadol), first approved Aug 22, 1978, with 3 new uses approved and 0 published complete response letters.
| Butorphanol Tartrate | Part D | $1.9M | -5% | 2,479 |
| Butorphanol Tartrate | Part B | $4K | +175% | 127 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Butorphanol for Pain Relief After Cesarean Section: A Retrospective StudyCaesarean Section · Sichuan Provincial People's Hospital | — | Not yet recruiting | Sep 16, 2025 |
| Aug 22, 1978 | Stadol Preservative Free, StadolNDA 17857 · New molecular entity | Apothecon | 44 | Discontinued |
| Dec 12, 1991 | StadolNDA 19890 · New dosage form | Bristol Myers Squibb | 16 | Discontinued |
| Jan 22, 1997 | Butorphanol Tartrate Preservative FreeANDA 74620 | Hospira | 2 | Discontinued |
| Jan 23, 1997 | Butorphanol Tartrate Preservative FreeANDA 74626 | Hospira | 22 | Marketed |
| Aug 12, 1998 | Butorphanol Tartrate Preservative FreeANDA 75045 | Hikma | 7 | Marketed |
| Aug 12, 1998 | Butorphanol TartrateANDA 75046 | Hikma | 7 | Marketed |
| Sep 28, 1998 | Butorphanol Tartrate Preservative FreeANDA 75170 | Hospira | 8 | Discontinued |
| Nov 4, 1999 | Butorphanol TartrateANDA 75342 | Hospira | 0 | Discontinued |
| Mar 20, 2000 | Butorphanol TartrateANDA 75559 | Hospira | 4 | Discontinued |
| Aug 8, 2001 | Butorphanol TartrateANDA 75759 | Rising | 17 | Discontinued |
| Oct 23, 2001 | Butorphanol Tartrate Preservative FreeANDA 75695 | Baxter Hlthcare Corp | 5 | Discontinued |
| Oct 23, 2001 | Butorphanol TartrateANDA 75697 | Baxter Hlthcare Corp | 4 | Discontinued |
| Mar 12, 2002 | Butorphanol TartrateANDA 75824 | Hikma | 11 | Marketed |
| Dec 4, 2002 | Butorphanol TartrateANDA 75499 | Apotex | 16 | Marketed |
| Apr 29, 2009 | Butorphanol TartrateANDA 78247 | Hikma Farmaceutica | 6 | Discontinued |
| May 1, 2009 | Butorphanol TartrateANDA 78400 | Hikma Farmaceutica | 6 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA